Immunostimulatory compounds are essential components in modern vaccines, acting to enhance the immune system's response to an introduced antigen. These compounds, often adjuvants like aluminum salts or newer agents such as lipid nanoparticles and synthetic molecules, stimulate the immune system by activating key cellular pathways. This helps the body recognize and respond more vigorously to the vaccine, creating a stronger, longer-lasting immunity. Immunostimulants are especially valuable in vaccines designed for diseases that evade immune detection, such as certain viral infections and cancers, as they improve the immune system’s ability to detect and fight these complex pathogens. By carefully choosing and combining these compounds, vaccine developers can create formulations that elicit a potent immune response, potentially requiring fewer doses and offering more robust protection across diverse patient populations. This makes immunostimulatory compounds a cornerstone of effective and durable vaccine development.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States